- The P-III LELANTOS-2 study will assess Pamrevlumab + systemic corticosteroids vs PBO + systemic corticosteroids in ~70 patients aged 6-12yrs. in a ratio (1:1) with ambulatory DMD for up to 52wks.
- The focus of the study is to assess the effect of Pamrevlumab on muscle function in patients with DMD with 1EPs as an ambulatory function assessment, measured by NSAA. Additionally, 2EPs will be assessed in the study
- Patients who complete the 52wks. study will be eligible for rollover into an OLE study with Pamrevlumab and systemic corticosteroids. Pamrevlumab is a first-in-class antibody that inhibits the activity of CTGF
Click here to read full press release/ article | Ref: Fibrogen | Image: Fibrogen